Related Experiment Video
Updated: Apr 15, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.7K
New systemic therapies for psoriasis
Yasaman Mansouri, Gary Goldenberg1
15 E 98th St, 5th Floor, New York, NY 10029-6574, USA. garygoldenbergmd@gmail.com.
Cutis
|April 7, 2015
Summary
New biologic drugs and small molecule inhibitors, including IL-17 and IL-23 blockers, PDE4, and JAK inhibitors, are revolutionizing psoriasis treatment options.
Area of Science:
- Dermatology and immunology, focusing on therapeutic advancements.
Background:
- Psoriasis treatment has evolved significantly due to a deeper understanding of its pathogenesis.
- Biologic drugs and small molecule inhibitors represent major advancements in systemic therapy.
Purpose of the Study:
- To review recently approved and emerging systemic treatments for psoriasis.
- To discuss the roles of IL-17 inhibitors, IL-23 blockers, PDE4 inhibitors, and JAK inhibitors.
Main Methods:
- Literature review of recently approved and pipeline systemic agents for psoriasis.
- Categorization of treatments into biologics and small molecule inhibitors.
Main Results:
- Biologics targeting IL-17 and IL-23 pathways offer novel therapeutic options.
- Small molecule inhibitors, including PDE4 and JAK inhibitors, provide oral administration alternatives.
Conclusions:
- The landscape of psoriasis treatment is rapidly expanding with new biologic and small molecule therapies.
- These advancements offer improved efficacy and patient-friendly administration routes for managing psoriasis.
Related Concept Videos
01:27Acne Infection
72
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
72
01:29Inflammatory Bowel Disease IV: Pharmacological Management
991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
991
01:29Drugs for Treatment of Ulcerative Colitis in IBD
667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
01:28Drug Therapy
418
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
418
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
721
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
721